ARIXTRA 7.5MG INJECTION belongs to a class of drugs called anticoagulants (blood thinner) primarily used to prevent/treat deep vein thrombosis (blood clots in leg veins), pulmonary embolism (blood clots in the lung), heart attack, and severe angina. It also reduces the risk of blood clots after orthopedic (such as hip or knee surgery), or abdominal surgery. ARIXTRA 7.5MG INJECTION prevents blood clot formation during and shortly after restricted movement because of an acute illness. Deep vein thrombosis is a medical condition in which blood clots form in deep veins, usually in the legs. Pulmonary embolism is a condition in which a blood clot blocks the arteries in the lungs.

ARIXTRA 7.5MG INJECTION contains ‘Fondaparinux sodium’ that works by inhibiting the action of clotting factors (a natural substance in the blood that causes clotting). Thereby preventing the conversion of fibrinogen to fibrin (a protein that binds platelets together and forms a clot) and helping prevent blood clot formation. It eases blood flow through the veins, making it less likely to develop a severe blood clot.

ARIXTRA 7.5MG INJECTION will be administered by a trained healthcare professional; hence do not self-administer. Some people may experience unusual bleeding, anemia (low number of red blood cells), bruising or swelling. Most of these side effects of ARIXTRA 7.5MG INJECTION do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.

If you are pregnant or breastfeeding, it is advised to consult a doctor before using ARIXTRA 7.5MG INJECTION. ARIXTRA 7.5MG INJECTION is not recommended for children below 17 years of age. ARIXTRA 7.5MG INJECTION should be used with caution in the elderly above 60, as they may be at high risk of bleeding. If you have a stomach ulcer, kidney or liver problems, high blood pressure, or bleeding problems, inform your doctor before receiving ARIXTRA 7.5MG INJECTION. If you are about to undergo surgery, inform your doctor about the treatment with ARIXTRA 7.5MG INJECTION. Keep your doctor informed about your health condition and medications to rule out any interactions.

ARIXTRA 7.5MG INJECTION belongs to a class of drugs known as anticoagulants or blood thinners. ARIXTRA 7.5MG INJECTION contains ‘Fondaparinux sodium’ used to prevent deep vein thrombosis (blood clot in the blood vessels of legs) and pulmonary embolism (blood clot in the blood vessels lungs). It also reduces the risk of blood clots during orthopedic (such as hip or knee surgery), abdominal surgery, or restricted movement because of an acute illness. ARIXTRA 7.5MG INJECTION works by stopping the action of clotting factor Xa (a natural substance in the blood that causes clotting). This inhibits fibrin production (a protein that binds platelets together and forms a clot), preventing blood clot formation. ARIXTRA 7.5MG INJECTION is also used to treat certain types of heart attack and chest pain called unstable angina.

Do not receive ARIXTRA 7.5MG INJECTION if you are allergic to any of the contents; if you are bleeding excessively, have a bacterial heart infection, or have very severe kidney disease. If you are pregnant or breastfeeding, it is advised to consult a doctor before using ARIXTRA 7.5MG INJECTION. ARIXTRA 7.5MG INJECTION is not recommended for children as safety and effectiveness have not been established. ARIXTRA 7.5MG INJECTION should be used with caution in the elderly above 65, as they may be at high risk of bleeding. If you are about to undergo any surgery, inform your doctor that you are receiving ARIXTRA 7.5MG INJECTION. If you notice bleeding gums, blood in urine, coughing up blood or vomit that looks like coffee grounds, pain, swelling, dizziness, weakness, unusual bruising, nose bleeds, abnormal vaginal bleeding or heavy menstrual periods, bloody or tarry stools, please consult a doctor immediately. Avoid alcohol consumption during treatment with ARIXTRA 7.5MG INJECTION as it may increase the risk of stomach bleeding. Inform your doctor before receiving ARIXTRA 7.5MG INJECTION if you have a stomach ulcer, kidney or liver problems, high blood pressure, bleeding problems, are 75 years or older, or weigh less than 50kg. Do not discontinue using ARIXTRA 7.5MG INJECTION without consulting your doctor, as this may increase your chances of having another heart attack or stroke.

• To analyze your blood clotting time, regular tests such as platelet count, factor V assay, fibrinogen level test, prothrombin time test (PT or PT-INR) and INR (International Normalized Ratio) are advised.

Blood clot: A blood clot is a clump of blood that has changed from a liquid to a gel-like or semisolid state. Blood clots are formed to stop bleeding that occurs due to tissue injury. Though blood clots help stop bleeding, they may be harmful when abnormally formed within blood vessels as they block blood vessels, inhibit blood flow to essential organs such as the brain, heart or lungs, and result in severe conditions. The common risk factors for blood clots are obesity, smoking, cancer, family history of blood clots, age over 65, and certain birth control pills or pregnancy.

Deep vein thrombosis: Deep vein thrombosis (blood clots in the legs) is a medical condition in which blood clots form in deep veins, usually in the legs. The symptoms include leg pain or swelling. 

Pulmonary embolism: Pulmonary embolism (blood clots in the lung) is a blockage in the lung arteries. It is caused by blood clots that travel from the legs or other body parts. The symptoms of pulmonary embolism include chest pain, cough, and shortness of breath.